Clinical trial
The ELDORADO (Eligard®, Docetaxel and Radiotherapy) Study
NCT00452556 · Nova Scotia Cancer Centre, Other · Unknown status
Key facts
| NCT number | NCT00452556 |
|---|---|
| Title | The ELDORADO (Eligard®, Docetaxel and Radiotherapy) Study |
| Official title | The ELDORADO (Eligard®, Docetaxel and Radiotherapy) Study: A Phase II Study of Chemo - Hormonal Therapy and Radiation in High Risk Prostate Cancer |
| Lead sponsor | Nova Scotia Cancer Centre, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms |
| Intervention type | Drug, Radiation |
| Interventions | Docetaxel, Leuprolide Acetate (Eligard®), Intensity-Modulated Radiotherapy |
| Enrollment | 86 |
| Start date | May 1, 2007 |
| Primary completion | Feb 1, 2017 |
| Completion | Feb 1, 2017 |
| First posted | Mar 27, 2007 |
| Last update posted | Mar 19, 2014 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: